

Ryan Kolb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/624658/publications.pdf>

Version: 2024-02-01

25
papers

1,317
citations

516710

16
h-index

713466

21
g-index

26
all docs

26
docs citations

26
times ranked

2372
citing authors

#	ARTICLE	IF	CITATIONS
1	Obesity and cancer: inflammation bridges the two. <i>Current Opinion in Pharmacology</i> , 2016, 29, 77-89.	3.5	266
2	Inflammasomes in cancer: a double-edged sword. <i>Protein and Cell</i> , 2014, 5, 12-20.	11.0	221
3	Obesity-associated NLRC4 inflammasome activation drives breast cancer progression. <i>Nature Communications</i> , 2016, 7, 13007.	12.8	186
4	Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4. <i>Oncogene</i> , 2019, 38, 2351-2363.	5.9	83
5	Differential Expression of CXCL12 and CXCR4 During Human Fetal Neural Progenitor Cell Differentiation. <i>Journal of NeuroImmune Pharmacology</i> , 2007, 2, 251-258.	4.1	62
6	IL-1 Signaling in Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1240, 1-23.	1.6	60
7	Beneficial and Detrimental Roles of NLRs in Carcinogenesis. <i>Frontiers in Immunology</i> , 2013, 4, 370.	4.8	53
8	Paracrine WNT5A Signaling Inhibits Expansion of Tumor-Initiating Cells. <i>Cancer Research</i> , 2015, 75, 1972-1982.	0.9	53
9	Obesity and Breast Cancer: A Case of Inflamed Adipose Tissue. <i>Cancers</i> , 2020, 12, 1686.	3.7	50
10	Involvement of the NLRC4-Inflammasome in Diabetic Nephropathy. <i>PLoS ONE</i> , 2016, 11, e0164135.	2.5	42
11	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. <i>Journal of Molecular Biology</i> , 2018, 430, 2014-2029.	4.2	42
12	Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5856.	3.7	39
13	CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells. <i>Nature Communications</i> , 2021, 12, 5764.	12.8	38
14	Characterization of a novel mouse model with genetic deletion of CD177. <i>Protein and Cell</i> , 2015, 6, 117-126.	11.0	36
15	Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. <i>Nature Communications</i> , 2021, 12, 1281.	12.8	34
16	Re-Evaluating E-Cadherin and β -Catenin. <i>American Journal of Pathology</i> , 2018, 188, 1910-1920.	3.8	20
17	Cancer cell-intrinsic function of CD177 in attenuating β -catenin signaling. <i>Oncogene</i> , 2020, 39, 2877-2889.	5.9	11
18	ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer. <i>Cancers</i> , 2019, 11, 718.	3.7	9

#	ARTICLE	IF	CITATIONS
19	Transcriptome analysis of basal and luminal tumor-initiating cells in ErbB2-driven breast cancer. Genomics Data, 2015, 4, 119-122.	1.3	4
20	ROR1 is an Intriguing Target for Cancer Therapy. Molecular Enzymology and Drug Targets, 2016, 02, .	0.1	2
21	Abstract 2083: WNT5a/ROR1 axis in triple-negative breast cancer progression and potential therapy. Cancer Research, 2014, 74, 2083-2083.	0.9	2
22	Abstract 2470: Cd177, a novel metastasis suppressor of breast cancer. , 2014, , .		0
23	Abstract 3173: The NLRC4 inflammasome promotes breast cancer progression in diet-induced obese mice. , 2015, , .		0
24	Abstract B20: Obesity-induced Nlrc4 inflammasome promotes angiogenesis in breast cancer. , 2016, , .		0
25	Abstract 5529: CD177 suppresses breast cancer progression by regulating the canonical WNT β -Catenin pathway. , 2017, , .		0